Drug Profile
Measles, mumps, rubella and varicella vaccine - Zydus Lifesciences
Alternative Names: MMR varicella zoster virus vaccine - Zydus LifesciencesLatest Information Update: 21 Mar 2022
Price :
$50
*
At a glance
- Originator Cadila Healthcare
- Developer Zydus Lifesciences
- Class Measles vaccines; Mumps vaccines; Rubella vaccines; Varicella vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Measles; Mumps; Rubella; Varicella zoster virus infections
Most Recent Events
- 28 Nov 2018 No recent reports of development identified for phase-I development in Measles(Prevention, In volunteers) in India (SC, Injection)
- 28 Nov 2018 No recent reports of development identified for phase-I development in Mumps(Prevention, In volunteers) in India (SC, Injection)
- 28 Nov 2018 No recent reports of development identified for phase-I development in Rubella(Prevention, In volunteers) in India (SC, Injection)